Cell culture materials impact a target cell’s ability to proliferate and function as planned. These materials offer precise mechanical and chemical cues that decide a cell's morphology and ...
HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
A study provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and describes their different immunomodulatory roles in the tumor environment. The results ...
On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results